|
|
 |
|
Viewing report
|
|
|
|
Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism
GBI Research, Sep 2011, Pages: 98
“Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism” provides a robust idea about patient recruitment status by geography, sponsor companies and year for all the major CVD indications. Furthermore, the report provides prevalence forecast data to 2017 for all the major CVD indications. The major indications covered in the report are hypertension, atrial fibrillation, dyslipidemia and venous thromboembolism. The report was built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
There has been an increase in the number of clinical trials conducted for cardiovascular diseases (CVD) due to the high prevalence of CVD. According to the American Heart Association’s (AHA) 2006 data, around 81.1 million people in the US suffer from CVD and one in every 2.9 deaths in the US is due to CVD. According to the European Heart Network’s 2008 data, CVD caused 4.3 million deaths (48%) in Europe. The high prevalence and mortality rate associated with CVD has led to an increase in research and development (R&D) activity by pharmaceutical companies.
Clinical trials are one of the most critical parts of the drug development process. The various aspects involved in clinical trials, such as the implementation of technology, efficient supply chain management, proper site selection, patient recruitment and database management among others, are crucially important. Clinical trial recruitment is a time intensive process so good strategies must be followed by pharmaceutical companies for proper patient recruitment.
Efficient patient recruitment leads to a decrease in the time and cost associated with patient recruitment. At present, the rate of new drug approvals is declining as pharmaceutical companies are under intense pressure to reduce the time required for drug development. It is equally important to cut the costs of clinical trials through proper patient recruitment. The delay in recruitment time is responsible for the increase in the timeline of clinical trial completion, the increase in costs to conduct the clinical trial and a delay in the time to market. There are many barriers to participation for the patients and for investigators who enroll the patients into the trials.
To complete the trial recruitment targets set by the sponsors or clinical research organizations (CROs), proper strategies must be planned in the initial phases of the trial. This will help to save time as well as costs in reaching the optimum patient pool for statistical analysis. If the recruitment is faster in the early stages of the trial, high and low potential sites can be identified. High-recruiting sites can then be allowed by the sponsors to exceed their targets in order to compensate for low recruiting sites.
Scope
The report analyzes the clinical trial recruitment trends of pharmaceutical companies for various cardiovascular trials. Its scope includes -
- Insight on clinical trials conducted for major indications of cardiology such as hypertension, atherosclerosis, atrial fibrillation and venous thromboembolism from 2000-2009.
- The status of patient recruitment by geography, sponsor company, year and stage of development.
- Analysis on the average number of patients recruited per trial for major indications per year.
- Analysis on the average number of patients recruited per trial for major indications by stage of development.
- The prevalence population in India, China and Brazil for all major indications from 2010-2017.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Identify and understand the status of clinical trials conducted for major cardiology indications from 2000-2009.
- Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.
- Identify the prevalence population for the major indications till 2017.
- Identify the average number of patients recruited by stage of development and across years for all major indications.
- Identify the indication in which the maximum number of trials is conducted and maximum number of patients recruited.
|
|
|
|
